News | Ventricular Assist Devices (VAD) | May 29, 2020

Class I Recall Issued for Medtronic HeartWare HVAD Pump

Outflow graft and strain relief recalled due to risk of breaks and tears during set up

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump

May 29, 2020 — Medtronic is recalling its HeartWare HVAD left ventricular assist device (LVAD) pump outflow graft and outflow graft strain relief because it may tear and the strain relief screw may break during assembly prior to implant. Medtronic said the issues might not be observed until during or after the pre-implant pump assembly and attachment to the HVAD pump.

Medtronic has received 92 complaints related to the pre-implant pump assembly process, which includes both the strain relief screw breaking and outflow graft tears. The recall in the U.S. includes 4,924 devices. The recall was initiated April 3, 2020,

The FDA says this is a Class I recall because use of these affected products may cause serious patient harm including dizziness, loss of consciousness, bleeding, fluid buildup around the heart, additional medical procedures or even death.

Read the FDA recall

The recalled medical products include:
   • HVAD Pump Outflow Graft: 1125
   • HVAD Pump Implant Kit: 1103
   • HVAD Implant Accessories Kit: 1153

The HeartWare HVAD Pump Outflow Graft and Outflow Graft Strain Relief, are parts of the HeartWare Ventricular Assist Device (HVAD) System, that help the heart deliver blood to the rest of the body. The HVAD system is used as a bridge to cardiac transplants in patients who are at risk of death from end-stage left ventricular heart failure, for heart tissue recovery, or as destination therapy (DT) in patients where new transplants are not planned.

 


Related Content

News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
News | Heart Failure

March 25, 2025 — Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive ...

Home March 25, 2025
Home
News | Heart Failure

March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new ...

Home March 21, 2025
Home
News | Heart Failure

Jan. 7, 2025 — FIRE1 recently announced it has received Breakthrough Device Designation from the U.S. Food and Drug ...

Home January 07, 2025
Home
Subscribe Now